Alder Biopharmaceuticals Revenue and Competitors

Seattle, WA USA

Location

$525M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Alder Biopharmaceuticals's estimated annual revenue is currently $5.4M per year.(i)
  • Alder Biopharmaceuticals received $287.5M in venture funding in February 2018.
  • Alder Biopharmaceuticals's estimated revenue per employee is $77,500
  • Alder Biopharmaceuticals's total funding is $525M.

Employee Data

  • Alder Biopharmaceuticals has 70 Employees.(i)
  • Alder Biopharmaceuticals grew their employee count by -34% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M6200%N/AN/A
#2
$1.1M7-36%N/AN/A
#3
$4.8M3119%N/AN/A
#4
$1.3M17-23%N/AN/A
#5
$31.6M1633%$30.2MN/A
#6
$1.9M120%N/AN/A
#7
$4.2M27-16%N/AN/A
#8
$2.5M16-27%N/AN/A
#9
$0.9M60%N/AN/A
#10
$2.8M180%N/AN/A
Add Company

Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$525M

Total Funding

70

Number of Employees

$5.4M

Revenue (est)

-34%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Alder Biopharmaceuticals News

2022-04-17 - How Covid-19 Outbreak Affected The Sales Of Th17 Driven ...

... market players in Th17 Driven disease Treatment market are AbbVie, Alexion Pharmaceuticals, Alder Biopharmaceuticals, Astellas Pharma.

2022-04-13 - Evanston woman sentenced to prison, fined $100K on insider ...

... Grevas, made $286,960 in illegal profits from the purchase and sale of securities in Washington state-based Alder BioPharmaceuticals,...

2022-03-30 - Latest drama at Athira: Investor calls for CEO replacement and wants two board seats

A billionaire investor of Athira Pharma is calling for the ouster of ... the former chief business officer at Alder Biopharmaceuticals and...

2019-09-16 - Lundbeck to Buy Alder BioPharmaceuticals, For Up To USD 1.95 Billion

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY), a Valby, Denmark-based global pharmaceutical company specialized in brain diseases, is to acquire Alder BioPharmaceuticals (NASDAQ: ALDR), a Bothell, Washington, USA-based company committed to advancing migraine treatment and prevention, in a transaction ...

2019-09-16 - Lundbeck to acquire Alder BioPharmaceuticals for nearly $2B

Alder’s lead drug candidate is eptinezumab, a monoclonal antibody for migraine prevention that targets the calcinonin gene-related peptide, or CGRP, and has been submitted to the FDA for approval, with the agency expected to rule on the drug by Feb. 21, 2020. Shares of Alder were up 83 percent ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.4M714%N/A
#2
$9.5M73N/AN/A
#3
$11.3M7826%N/A
#4
$19.8M798%N/A
#5
$21.3M79-11%N/A

Alder Biopharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2005-08-16$11.1MAMultipleArticle
2006-07-10$16.0MBH.I.G. VenturesArticle
2008-01-14$40.0MCTPG Biotech, Delphi VenturesArticle
2012-04-20$38.0MDNovo VenturesArticle
2012-08-28$3.5MUndisclosedBristol-Myers SquibbArticle
2015-01-09$177.0MUndisclosedCredit SuisseArticle
2015-06-26$230.0MUndisclosedCredit SuisseArticle
2017-07-14$172.5MUndisclosedLeerink Partners LLCArticle
2018-01-09$100.0MUndisclosedRedmile Group LLCArticle
2018-01-30$230.0MUndisclosedGoldman Sachs & Co. LLC,Article
2018-02-05$287.5MUndisclosedGoldman Sachs & Co. LLC,Article